Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Hematuria is the presence of blood in the urine. Although blood in the urine is not always a significant symptom of disease, it can be an important warning sign of a potential health problem. Bloody urine should never be ignored. Hematuria treatment largely depends on the actual cause of the presence of blood in the urine. Infections such as urinary tract infection, kidney stone, injury due to sports, more serious problems such as kidney or bladder cancer, sickle cell disease can be some of the causes of hematuria. Information collected such as medical history, physical exam, and test results are used to determine the best treatment option. Also in some cases people that are susceptible of getting hematuria is family history of kidney disease, an enlarged prostate, bladder or kidney stones, among other reasons.
The hematuria treatment market in Asia Pacific region is expected to witness consistent growth in the coming years owing to factors such as the increasing prevalence of chronic kidney disorders also technological developments in medical devices and diagnostic procedures have contributed to the growth of the market. Various options for managing hematuria-associated indications, such as kidney stones, bladder stones, and urinary tract infections and use of advanced treatment technologies is expected to enhance patient care are some of the major characteristics fueling the growth of the market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the Asia Pacific hematuria treatment market. In addition, complete analysis of changes on the Asia Pacific hematuria treatment market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on Asia Pacific economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 pandemic has caused substantial damage to the health. However, this virus can also affect the kidney as kidney dysfunctions were observed in large proportion infected with coronavirus disease. Thus the pandemic contributed positively in the growth of hematuria treatment market in the region.
The hematuria treatment market comprises of different market segment like type, indication, treatment, end user and country.
The hematuria treatment is available in market according different type including macroscopic hematuria, microscopic hematuria, idiopathic hematuria, jogger’s hematuria. Macroscopic hematuria is visible blood in the urine in which the urine appears pink, red, reddish-brown, or tea-colored. The microscopic hematuria is where there is no visual evidence of the presence of blood unless the urine is examined under the microscope. In idiopathic hematuria there is no specific cause for the appearance of blood in the urine also in case of family history where there is no case of kidney disease there is no specific treatment required to treat the idiopathic hematuria. Jogger’s hematuria is often caused due to rigorous exercise and may have causes ranging from serious to harmless.
The hematuria treatment market has different indication like urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, menstruation. Some of the main symptoms and causes of hematuria include inflammation of the kidney, urethra, bladder or prostate in men. Abnormal urinary tract structures, hereditary diseases such as polycystic kidney disease, sickle cell anemia or hemophilia, mineral imbalances in the urine, symptoms depends on the site of infection but may include severe pain on one side of the middle back, chills, fever, nausea and vomiting, pain above the pubic bone or bladder region. In most cases, hematuria is due to a urinary tract or kidney infection.
The hematuria treatment market includes different treatments such as drugs, therapies. A health care professional diagnoses hematuria or the cause of the hematuria with a medical history, physical exam, urinalysis and some additional testing. Hematuria treatment depends on the following tests and the type of hematuria detected. Also in case of no family history of kidney disorder no specific treatment is required to treat the hematuria. The serious causes of hematuria such as kidney or bladder cancer, polycystic kidney disease, sickle cell disease or family history of kidney disease requires multiple tests to detect the cause and advance treatment to cure hematuria.
The hematuria treatment market finds its major end user in hospitals, clinics, ambulatory surgical centers, others. The presence of blood in the urine is a sign of hematuria and need to be diagnosed and treated on time. The healthcare professional advice and early detection and diagnosis help to reduce the severity of the disease. With the increasing advancement in the healthcare sector and various test and proper medication helps to reduce the severity and cure the disease if diagnosed at early stage. Increasing awareness about treatment options and increase in healthcare expenditure are driving the market growth.
The Asia Pacific hematuria treatment market is studied for the following countries like China, India, Japan and Rest of Asia Pacific among others. The increasing use of advanced treatment technologies is expected to the growth of hematuria treatment market in the region. The increasing government investment in the healthcare sector and incase in the populations healthcare expenditure due implementation of robotics in surgeries for treating urolithiasis has gained popularity in recent years. The increasing aging population which is more likely to suffer hematuria symptoms also the researchers discovered a significant variance in the prevalence of chronic kidney disease is predicted to drive market in the forecast period.
The key players in hematuria treatment market are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH and The Medicines Company among others.
September 2021: AstraZeneca collaborated with VaxEquity for the discovery, development, and commercialization of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.
September 2021: Merck announced its definitive agreement to acquire Acceleron. Following the purchase of shares in the tender offer, Acceleron will become a subsidiary of Merck.
August 2021: Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for anticancer treatments.
June 2021: Eisai Co., Ltd. and Bristol-Myers Squibb Company entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
July 2021: GlaxoSmithKline plc. and Alector, announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.
The report analyses the hematuria treatment market based on by type, indication, treatment, end user and country. The hematuria treatment is available in market according different type including macroscopic hematuria, microscopic hematuria, idiopathic hematuria, jogger’s hematuria. Macroscopic hematuria is visible blood in the urine in which the urine appears pink, red, reddish-brown, or tea-colored. The hematuria treatment market has different indication like urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, menstruation. The hematuria treatment market includes different treatments such as drugs, therapies. A health care professional diagnoses hematuria or the cause of the hematuria with a medical history, physical exam, urinalysis and some additional testing. The hematuria treatment market finds its major end user in hospitals, clinics, ambulatory surgical centers, others. The presence of blood in the urine is a sign of hematuria and need to be diagnosed and treated on time. The healthcare professional advice and early detection and diagnosis help to reduce the severity of the disease. The Asia Pacific hematuria treatment market is studied for the following countries like China, India, Japan and Rest of Asia Pacific among others.
Why to buy this report
